Subject
Immunology and Allergy,Immunology,Pulmonary and Respiratory Medicine
Reference34 articles.
1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014
2. European Medicine Agency (Ema). https://www.ema.europa.eu/en/documents/overview/nucala-epar-medicine-overview_en.pdf Last accessed 25 november 2019.
3. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial;Chupp;Lancet Respir Med,2017
4. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial;Pavord;Lancet,2012
5. MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma;Ortega;N Engl J Med,2014
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献